


List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2423827/publications.pdf Version: 2024-02-01



SIEW C NO

#	Article	IF	CITATIONS
1	Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. Inflammatory Bowel Diseases, 2023, 29, 85-96.	1.9	7
2	Herpes Zoster and Vaccination Strategies in Inflammatory Bowel Diseases: A Practical Guide. Clinical Gastroenterology and Hepatology, 2022, 20, 481-490.	4.4	19
3	Risks of post-colonoscopic polypectomy bleeding and thromboembolism with warfarin and direct oral anticoagulants: a population-based analysis. Gut, 2022, 71, 100-110.	12.1	22
4	Microbiota engraftment after faecal microbiota transplantation in obese subjects with type 2 diabetes: a 24-week, double-blind, randomised controlled trial. Gut, 2022, 71, 716-723.	12.1	83
5	Underdevelopment of the gut microbiota and bacteria species as non-invasive markers of prediction in children with autism spectrum disorder. Gut, 2022, 71, 910-918.	12.1	66
6	Targeting the Gut Microbiota in Coronavirus Disease 2019: Hype or Hope?. Gastroenterology, 2022, 162, 9-16.	1.3	16
7	Worldwide postâ€marketing safety surveillance experience with tofacitinib in ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2022, 55, 302-310.	3.7	16
8	Prolonged Impairment of Short-Chain Fatty Acid and L-Isoleucine Biosynthesis in Gut Microbiome in Patients With COVID-19. Gastroenterology, 2022, 162, 548-561.e4.	1.3	131
9	Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut, 2022, 71, 544-552.	12.1	273
10	Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review. Gastroenterology, 2022, 162, 1147-1159.e4.	1.3	192
11	The Multiple Waves of COVID-19 in Patients With Inflammatory Bowel Disease: A Temporal Trend Analysis. Inflammatory Bowel Diseases, 2022, , .	1.9	7
12	Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. The Lancet Gastroenterology and Hepatology, 2022, 7, 254-261.	8.1	18
13	Gut microbiota in patients with obesity and metabolic disorders — a systematic review. Genes and Nutrition, 2022, 17, 2.	2.5	67
14	An update on the roles of circular RNAs in spinal cord injury. Molecular Neurobiology, 2022, 59, 2620-2628.	4.0	6
15	Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events. Gut, 2022, 71, 1106-1116.	12.1	84
16	Emerging Roles of Long Non-Coding RNAs in Ankylosing Spondylitis. Frontiers in Immunology, 2022, 13, 790924.	4.8	6
17	Efficacy of international webâ€based educational intervention in the detection of highâ€risk flat and depressed colorectal lesions higher (CATCH project) with a video: Randomized trial. Digestive Endoscopy, 2022, 34, 1166-1175.	2.3	2
18	Altered gut metabolites and microbiota interactions are implicated in colorectal carcinogenesis and can be non-invasive diagnostic biomarkers. Microbiome, 2022, 10, 35.	11.1	81

#	Article	IF	CITATIONS
19	Reply. Gastroenterology, 2022, , .	1.3	0
20	Reply: Gut microbiome metabolism drives the resolution of patients with COVID-19?. Gastroenterology, 2022, , .	1.3	0
21	Gut microbiotaâ€derived synbiotic formula (SIM01) as a novel adjuvant therapy for COVIDâ€19: An openâ€label pilot study. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 823-831.	2.8	31
22	No increased risk of flare in ulcerative colitis patients in corticosteroidâ€free remission after stopping 5â€aminosalicylic acid: A territoryâ€wide populationâ€based study. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 1284-1289.	2.8	4
23	Indications, Postoperative Management, and Long-term Prognosis of Crohn's Disease After Ileocecal Resection: A Multicenter Study Comparing the East and West. Inflammatory Bowel Diseases, 2022, 28, S16-S24.	1.9	2
24	Dietary microbial modulation for colorectal cancer prevention in the Hong Kong Chinese population. , 2022, 28, 186-187.		0
25	Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus. The Lancet Gastroenterology and Hepatology, 2022, 7, 666-678.	8.1	31
26	Promises of microbiome-based therapies. Journal of Hepatology, 2022, 76, 1379-1391.	3.7	33
27	Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic. Gut, 2022, 71, 1426-1439.	12.1	20
28	Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression—risks, screening, diagnosis and management. Alimentary Pharmacology and Therapeutics, 2022, 56, 6-27.	3.7	17
29	Longitudinal Evaluation of Gut Bacteriomes and Viromes after Fecal Microbiota Transplantation for Eradication of Carbapenem-Resistant <i>Enterobacteriaceae</i> . MSystems, 2022, 7, .	3.8	5
30	Temporal trends in the epidemiology of inflammatory bowel diseases in the public healthcare system in Brazil: A large population-based study. The Lancet Regional Health Americas, 2022, 13, 100298.	2.6	9
31	Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19. Gut, 2021, 70, gutjnl-2020-322294.	12.1	314
32	An International Multicenter Comparison of IBD-Related Disability and Validation of the IBDDI. Clinical Gastroenterology and Hepatology, 2021, 19, 2524-2531.	4.4	5
33	Worldwide Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: An International Survey. Inflammatory Bowel Diseases, 2021, 27, 836-847.	1.9	21
34	Elucidation of Proteus mirabilis as a Key Bacterium in Crohn's Disease Inflammation. Gastroenterology, 2021, 160, 317-330.e11.	1.3	58
35	Population-Level Configurations of Gut Mycobiome Across 6 Ethnicities in Urban and Rural China. Gastroenterology, 2021, 160, 272-286.e11.	1.3	63
36	Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut, 2021, 70, 725-732.	12.1	240

#	Article	IF	CITATIONS
37	Bioinformatic analysis of SMN1–ACE/ACE2 interactions hinted at a potential protective effect of spinal muscular atrophy against COVID-19-induced lung injury. Briefings in Bioinformatics, 2021, 22, 1291-1296.	6.5	5
38	Review article: Probiotics, prebiotics and dietary approaches during COVID-19 pandemic. Trends in Food Science and Technology, 2021, 108, 187-196.	15.1	74
39	Development of an Openâ€Access and Explainable Machine Learning Prediction System to Assess the Mortality and Recurrence Risk Factors of <i>Clostridioides Difficile</i> Infection Patients. Advanced Intelligent Systems, 2021, 3, 2000188.	6.1	3
40	Streptococcus thermophilus Inhibits Colorectal Tumorigenesis Through Secreting β-Galactosidase. Gastroenterology, 2021, 160, 1179-1193.e14.	1.3	119
41	What Are the Most Challenging Aspects of Inflammatory Bowel Disease? An International Survey of Gastroenterologists Comparing Developed and Developing Countries. Inflammatory Intestinal Diseases, 2021, 6, 78-86.	1.9	6
42	The role of gut mycobiome in health and diseases. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110471.	3.2	39
43	Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut, 2021, 70, 698-706.	12.1	818
44	Transethnic analysis of the human leukocyte antigen region for ulcerative colitis reveals not only shared but also ethnicity-specific disease associations. Human Molecular Genetics, 2021, 30, 356-369.	2.9	19
45	Modulation of gut microbiota protects against viral respiratory tract infections: a systematic review of animal and clinical studies. European Journal of Nutrition, 2021, 60, 4151-4174.	3.9	25
46	SARS-CoV-2 vaccines and donor recruitment for FMT. The Lancet Gastroenterology and Hepatology, 2021, 6, 264-266.	8.1	5
47	Temporal landscape of human gut RNA and DNA virome in SARS-CoV-2 infection and severity. Microbiome, 2021, 9, 91.	11.1	40
48	Gut as viral reservoir: lessons from gut viromes, HIV and COVID-19. Gut, 2021, 70, 1605-1608.	12.1	34
49	Implications of COVID-19 for patients with pre-existing digestive diseases: an update. The Lancet Gastroenterology and Hepatology, 2021, 6, 258-260.	8.1	4
50	Reply. Gastroenterology, 2021, 160, 2193-2195.	1.3	1
51	Reply. Gastroenterology, 2021, 160, 2195-2196.	1.3	1
52	Glycemic and lipid variability for predicting complications and mortality in diabetes mellitus using machine learning. BMC Endocrine Disorders, 2021, 21, 94.	2.2	58
53	Microscopic colitis. Nature Reviews Disease Primers, 2021, 7, 39.	30.5	26
54	Development of a predictive risk model for all-cause mortality in patients with diabetes in Hong Kong. BMJ Open Diabetes Research and Care, 2021, 9, e001950.	2.8	17

#	Article	IF	CITATIONS
55	Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus. Autoimmunity Reviews, 2021, 20, 102849.	5.8	12
56	International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 857-873.	17.8	56
57	IDDF2021-ABS-0210â€Altered gut metabolites and bacterial interactions are implicated in colorectal carcinogenesis and can detect precancerous and cancerous lesions. , 2021, , .		0
58	The role of precision nutrition in the modulation of microbial composition and function in people with inflammatory bowel disease. The Lancet Gastroenterology and Hepatology, 2021, 6, 754-769.	8.1	27
59	Timing of endoscopy for acute upper gastrointestinal bleeding: a territory-wide cohort study. Gut, 2021, , gutjnl-2020-323054.	12.1	13
60	COVID-19 Outcomes Among Racial and Ethnic Minority Individuals With Inflammatory Bowel Disease in the United States. Clinical Gastroenterology and Hepatology, 2021, 19, 2210-2213.e3.	4.4	4
61	Alterations in the Gut Virome in Obesity and Type 2 Diabetes Mellitus. Gastroenterology, 2021, 161, 1257-1269.e13.	1.3	76
62	Prospective colonoscopic study to investigate risk of colorectal neoplasms in first-degree relatives of patients with non-advanced adenomas. Gut, 2020, 69, 304-310.	12.1	5
63	Progression of Inflammatory Bowel Diseases Throughout Latin America and the Caribbean: A Systematic Review. Clinical Gastroenterology and Hepatology, 2020, 18, 304-312.	4.4	129
64	Authors response: giant oversights in the human gut virome. Gut, 2020, 69, 1358.2-1358.	12.1	1
65	A novel faecal <i>Lachnoclostridium</i> marker for the non-invasive diagnosis of colorectal adenoma and cancer. Gut, 2020, 69, 1248-1257.	12.1	192
66	Human-Gut-DNA Virome Variations across Geography, Ethnicity, and Urbanization. Cell Host and Microbe, 2020, 28, 741-751.e4.	11.0	95
67	COVID-19 Pandemic: Which IBD Patients Need to Be Scoped—Who Gets Scoped Now, Who Can Wait, and how to Resume to Normal. Journal of Crohn's and Colitis, 2020, 14, S791-S797.	1.3	14
68	The Intersection between Oral Microbiota, Host Gene Methylation and Patient Outcomes in Head and Neck Squamous Cell Carcinoma. Cancers, 2020, 12, 3425.	3.7	33
69	The gut microbiome: an under-recognised contributor to the COVID-19 pandemic?. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482097491.	3.2	50
70	Changing Global Epidemiology of Inflammatory Bowel Diseases: Sustaining Health Care Delivery Into the 21st Century. Clinical Gastroenterology and Hepatology, 2020, 18, 1252-1260.	4.4	153
71	Tests that now deserve to be more widely adopted in IBD clinical practice. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482094408.	3.2	3
72	Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia. The Lancet Gastroenterology and Hepatology, 2020, 5, 1089-1100.	8.1	11

#	Article	IF	CITATIONS
73	Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia. The Lancet Gastroenterology and Hepatology, 2020, 5, 1076-1088.	8.1	32
74	Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology, 2020, 159, 481-491.e3.	1.3	613
75	Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology, 2020, 159, 944-955.e8.	1.3	1,072
76	The day after COVID-19 in IBD: how to go back to â€~normal'. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 441-443.	17.8	17
77	Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. The Lancet Gastroenterology and Hepatology, 2020, 5, 667-678.	8.1	804
78	Review article: bugs, inflammation and mood—a microbiotaâ€based approach to psychiatric symptoms in inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 2020, 52, 247-266.	3.7	26
79	Involvement of digestive system in COVID-19: manifestations, pathology, management and challenges. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482093462.	3.2	48
80	Embryonic gene expression altered by maternal exposure to air pollution in rats. Environmental Science and Pollution Research, 2020, 27, 31699-31705.	5.3	5
81	Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. The Lancet Gastroenterology and Hepatology, 2020, 5, 430-432.	8.1	108
82	Knowledge and Attitudes Towards Pregnancy in Females with Inflammatory Bowel Disease: An International, Multi-centre Study. Journal of Crohn's and Colitis, 2020, 14, 1248-1255.	1.3	27
83	Biological characteristics associated with virulence in <i>Clostridioides difficile</i> ribotype 002 in Hong Kong. Emerging Microbes and Infections, 2020, 9, 631-638.	6.5	4
84	Development and Validation of Surveys to Estimate Food Additive Intake. Nutrients, 2020, 12, 812.	4.1	3
85	Practice of endoscopy during COVID-19 pandemic: position statements of the Asian Pacific Society for Digestive Endoscopy (APSDE-COVID statements). Gut, 2020, 69, 991-996.	12.1	264
86	Alterations in Fecal Fungal Microbiome of Patients With COVID-19 During Time of Hospitalization until Discharge. Gastroenterology, 2020, 159, 1302-1310.e5.	1.3	237
87	Probiotics and COVID-19 – Authors' reply. The Lancet Gastroenterology and Hepatology, 2020, 5, 722-723.	8.1	6
88	Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. Gut, 2020, 69, 1555-1563.	12.1	110
89	Southern Chinese populations harbour non-nucleatum Fusobacteria possessing homologues of the colorectal cancer-associated FadA virulence factor. Gut, 2020, 69, 1998-2007.	12.1	42
90	Costâ€effectiveness analysis of fecal microbiota transplantation for recurrent <scp><i>Clostridium difficile</i></scp> infection in patients with inflammatory bowel disease. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1515-1523.	2.8	17

#	Article	IF	CITATIONS
91	Review article: prevention, diagnosis and management of COVIDâ€19 in the IBD patient. Alimentary Pharmacology and Therapeutics, 2020, 52, 54-72.	3.7	93
92	Probiotics and COVID-19: one size does not fit all. The Lancet Gastroenterology and Hepatology, 2020, 5, 644-645.	8.1	141
93	MicroRNAs in atopic dermatitis: A systematic review. Journal of Cellular and Molecular Medicine, 2020, 24, 5966-5972.	3.6	30
94	COVID-19 and the gastrointestinal tract: more than meets the eye. Gut, 2020, 69, 973-974.	12.1	167
95	Association of NPAC score with survival after acute myocardial infarction. Atherosclerosis, 2020, 301, 30-36.	0.8	28
96	Incidence of Celiac Disease Is Increasing Over Time: A Systematic Review and Meta-analysis. American Journal of Gastroenterology, 2020, 115, 507-525.	0.4	223
97	The use of 5-aminosalicylates in Crohn's disease: a retrospective study using the UK Clinical Practice Research Datalink. Annals of Gastroenterology, 2020, 33, 500-507.	0.6	4
98	IDDF2020-ABS-0194â€Timing of endoscopy for acute upper gastrointestinal bleeding: a territory-wide cohort study. , 2020, , .		0
99	Risk factors for advanced colorectal neoplasms in the proximal colon in 6218 subjects undergoing complete colonoscopy. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 113-119.	2.8	6
100	Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More. Inflammatory Intestinal Diseases, 2019, 4, 79-96.	1.9	53
101	Genomics and metagenomics of colorectal cancer. Journal of Gastrointestinal Oncology, 2019, 10, 1164-1170.	1.4	28
102	Eukaryotic elongation factor-2 kinase expression is an independent prognostic factor in colorectal cancer. BMC Cancer, 2019, 19, 649.	2.6	18
103	Aberrantly expressed long non oding RNAs in air pollutionâ€induced congenital defects. Journal of Cellular and Molecular Medicine, 2019, 23, 7717-7725.	3.6	14
104	Systematic review with metaâ€analysis: review of donor features, procedures and outcomes in 168 clinical studies of faecal microbiota transplantation. Alimentary Pharmacology and Therapeutics, 2019, 49, 354-363.	3.7	87
105	Review article: fungal alterations in inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 2019, 50, 1159-1171.	3.7	52
106	Stopping antiâ€ŧumour necrosis factor therapy in patients with perianal Crohn's disease. Alimentary Pharmacology and Therapeutics, 2019, 50, 1195-1203.	3.7	10
107	Translating the gut microbiome: ready for the clinic?. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 656-661.	17.8	33
108	Global smoking trends in inflammatory bowel disease: A systematic review of inception cohorts. PLoS ONE, 2019, 14, e0221961.	2.5	26

#	Article	IF	CITATIONS
109	Long nonâ€coding RNAs in the spinal cord injury: Novel spotlight. Journal of Cellular and Molecular Medicine, 2019, 23, 4883-4890.	3.6	20
110	Association of Cancer and the Risk of Developing Atrial Fibrillation: A Systematic Review and Meta-Analysis. Cardiology Research and Practice, 2019, 2019, 1-9.	1.1	34
111	Whole-genome sequencing reveals novel tandem-duplication hotspots and a prognostic mutational signature in gastric cancer. Nature Communications, 2019, 10, 2037.	12.8	55
112	MicroRNA signature of air pollution exposureâ€induced congenital defects. Journal of Cellular Physiology, 2019, 234, 17896-17904.	4.1	11
113	Gut mucosal virome alterations in ulcerative colitis. Gut, 2019, 68, 1169-1179.	12.1	289
114	Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries: a population-based study of countries in the Organisation for Economic Co-operation and Development. The Lancet Gastroenterology and Hepatology, 2019, 4, 287-295.	8.1	44
115	Impact of Preservation Method and 16S rRNA Hypervariable Region on Gut Microbiota Profiling. MSystems, 2019, 4, .	3.8	107
116	Sexâ€based differences in the incidence of inflammatory bowel diseases—pooled analysis of populationâ€based studies from the Asiaâ€Pacific region. Alimentary Pharmacology and Therapeutics, 2019, 49, 904-911.	3.7	48
117	Risk of Postpolypectomy Bleeding With Uninterrupted Clopidogrel Therapy in an Industry-Independent, Double-Blind, Randomized Trial. Gastroenterology, 2019, 156, 918-925.e1.	1.3	35
118	wtest: an integrated R package for genetic epistasis testing. BMC Medical Genomics, 2019, 12, 180.	1.5	8
119	The changing epidemiology of liver diseases in the Asia–Pacific region. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 57-73.	17.8	221
120	Population Density and Risk of Inflammatory Bowel Disease: A Prospective Population-Based Study in 13 Countries or Regions in Asia-Pacific. American Journal of Gastroenterology, 2019, 114, 107-115.	0.4	172
121	Risk of tuberculosis in patients with immune-mediated diseases on biological therapies: a population-based study in a tuberculosis endemic region. Rheumatology, 2019, 58, 803-810.	1.9	21
122	Effect of cultural background and healthcare environment on postoperative opioid requirement. Canadian Journal of Anaesthesia, 2019, 66, 309-317.	1.6	5
123	Standards of diagnostic colonoscopy for earlyâ€stage neoplasia: Recommendations by an Asian private group. Digestive Endoscopy, 2019, 31, 227-244.	2.3	15
124	Enteric fungal microbiota dysbiosis and ecological alterations in colorectal cancer. Gut, 2019, 68, 654-662.	12.1	325
125	New approaches along the IBD course: diet, tight control and stem cells. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 82-84.	17.8	14
126	Construction and benchmarking of a multi-ethnic reference panel for the imputation of HLA class I and II alleles. Human Molecular Genetics, 2019, 28, 2078-2092.	2.9	48

#	Article	IF	CITATIONS
127	Emerging roles of long nonâ€coding RNAs in neuropathic pain. Cell Proliferation, 2019, 52, e12528.	5.3	78
128	Impact of inter- and intra-individual variation, sample storage and sampling fraction on human stool microbial community profiles. PeerJ, 2019, 7, e6172.	2.0	17
129	Bacteriophage transfer during faecal microbiota transplantation in <i>Clostridium difficile</i> infection is associated with treatment outcome. Gut, 2018, 67, gutjnl-2017-313952.	12.1	241
130	A novel susceptibility locus in <i><scp>MST</scp>1</i> and geneâ€gene interaction network for Crohn's disease in the Chinese population. Journal of Cellular and Molecular Medicine, 2018, 22, 2368-2377.	3.6	10
131	NOVA1 acts as an oncogene in melanoma via regulating FOXO3a expression. Journal of Cellular and Molecular Medicine, 2018, 22, 2622-2630.	3.6	30
132	Urbanization and the gut microbiota in health and inflammatory bowel disease. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 440-452.	17.8	187
133	Cancer antigen-125 and risk of atrial fibrillation: a systematic review and meta-analysis. Heart Asia, 2018, 10, e010970.	1.1	17
134	Reduced lysosomal clearance of autophagosomes promotes survival and colonization of <i>Helicobacter pylori</i> . Journal of Pathology, 2018, 244, 432-444.	4.5	33
135	Reply. Gastroenterology, 2018, 154, 258-259.	1.3	0
136	Association Between Bacteremia From Specific Microbes and Subsequent Diagnosis of Colorectal Cancer. Gastroenterology, 2018, 155, 383-390.e8.	1.3	215
137	Alterations in Enteric Virome Are Associated With Colorectal Cancer and Survival Outcomes. Gastroenterology, 2018, 155, 529-541.e5.	1.3	271
138	Genotypeâ€guided warfarin dosing <i>vs</i> . conventional dosing strategies: a systematic review and metaâ€analysis of randomized controlled trials. British Journal of Clinical Pharmacology, 2018, 84, 1868-1882.	2.4	39
139	Development of an index to define overall disease severity in IBD. Gut, 2018, 67, 244-254.	12.1	108
140	Ethnicity Influences Phenotype and Outcomes in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis of Population-based Studies. Clinical Gastroenterology and Hepatology, 2018, 16, 190-197.e11.	4.4	84
141	Total cosine Râ€ŧoâ€ī for predicting ventricular arrhythmic and mortality outcomes: A systematic review and metaâ€analysis. Annals of Noninvasive Electrocardiology, 2018, 23, e12495.	1.1	11
142	Defective lysosomal clearance of autophagosomes and its clinical implications in nonalcoholic steatohepatitis. FASEB Journal, 2018, 32, 37-51.	0.5	60
143	Long non oding <scp>RNA</scp> s in rheumatoid arthritis. Cell Proliferation, 2018, 51, .	5.3	64
144	Adherent-invasive <i>Escherichia coli</i> in inflammatory bowel disease. Gut, 2018, 67, 574-587.	12.1	366

#	Article	IF	CITATIONS
145	Targeted Genotyping Identifies Susceptibility Locus in Brain-derived Neurotrophic Factor Gene for Chronic Postsurgical Pain. Anesthesiology, 2018, 128, 587-597.	2.5	26
146	Quantification of Beat-To-Beat Variability of Action Potential Durations in Langendorff-Perfused Mouse Hearts. Frontiers in Physiology, 2018, 9, 1578.	2.8	7
147	Cancer antigen-125 and outcomes in acute heart failure: a systematic review and meta-analysis. Heart Asia, 2018, 10, e011044.	1.1	26
148	Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting. Inflammatory Bowel Diseases, 2018, 24, 2431-2441.	1.9	77
149	The incidence of atrial fibrillation with trastuzumab treatment: A systematic review and metaâ€analysis. Cardiovascular Therapeutics, 2018, 36, e12475.	2.5	26
150	Higher Dispersion Measures of Conduction and Repolarization in Type 1 Compared to Non-type 1 Brugada Syndrome Patients: An Electrocardiographic Study From a Single Center. Frontiers in Cardiovascular Medicine, 2018, 5, 132.	2.4	17
151	T-Wave Indices and Atherosclerosis. Current Atherosclerosis Reports, 2018, 20, 55.	4.8	3
152	Sex-Based Differences in Incidence of Inflammatory Bowel Diseases—Pooled Analysis of Population-Based Studies From Western Countries. Gastroenterology, 2018, 155, 1079-1089.e3.	1.3	155
153	The Gut Microbiota in the Pathogenesis and Therapeutics of Inflammatory Bowel Disease. Frontiers in Microbiology, 2018, 9, 2247.	3.5	408
154	Gut fungal dysbiosis correlates with reduced efficacy of fecal microbiota transplantation in Clostridium difficile infection. Nature Communications, 2018, 9, 3663.	12.8	177
155	Significant Medical and Surgical Morbidity in Perianal Crohn's Disease: Results from a Territory-Wide Study. Journal of Crohn's and Colitis, 2018, 12, 1392-1398.	1.3	13
156	Reply. Clinical Gastroenterology and Hepatology, 2018, 16, 1177.	4.4	0
157	Atrial Fibrillation Recurrence and Peri-Procedural Complication Rates in nMARQ vs. Conventional Ablation Techniques: A Systematic Review and Meta-Analysis. Frontiers in Physiology, 2018, 9, 544.	2.8	5
158	Long non oding <scp>RNA</scp> s in nucleus pulposus cell function and intervertebral disc degeneration. Cell Proliferation, 2018, 51, e12483.	5.3	87
159	Plasminogen Activator Inhibitor 1 for Predicting Sepsis Severity and Mortality Outcomes: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 2018, 9, 1218.	4.8	50
160	Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers. Microbiome, 2018, 6, 70.	11.1	344
161	A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases. Journal of Crohn's and Colitis, 2018, 12, 954-962.	1.3	25
162	Proteus spp. as Putative Gastrointestinal Pathogens. Clinical Microbiology Reviews, 2018, 31, .	13.6	111

#	Article	IF	CITATIONS
163	Circulating microRNA signature of steroidâ€induced osteonecrosis of the femoral head. Cell Proliferation, 2018, 51, .	5.3	31
164	Epidemiology and Natural History of Fibrostenosing Inflammatory Bowel Disease. , 2018, , 5-12.		1
165	Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut, 2017, 66, 70-78.	12.1	865
166	Prevalence, distribution, and risk factor for colonic neoplasia in 1133 subjects aged 40–49 undergoing screening colonoscopy. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 92-97.	2.8	9
167	Peptostreptococcus anaerobius Induces Intracellular Cholesterol Biosynthesis in Colon Cells to Induce Proliferation and Causes Dysplasia in Mice. Gastroenterology, 2017, 152, 1419-1433.e5.	1.3	308
168	Mammalian TRAPPIII Complex positively modulates the recruitment of Sec13/31 onto COPII vesicles. Scientific Reports, 2017, 7, 43207.	3.3	32
169	Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. Lancet, The, 2017, 389, 2375-2382.	13.7	83
170	Neuroâ€oncological ventral antigen 1 (<scp>NOVA</scp> 1): Implications in neurological diseases and cancers. Cell Proliferation, 2017, 50, .	5.3	24
171	Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology, 2017, 153, 420-429.	1.3	1,983
172	Deep anesthesia: too much of a good thing?. Canadian Journal of Anaesthesia, 2017, 64, 574-580.	1.6	3
173	Cancer Risk in 2621 Chinese Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2017, 23, 2061-2068.	1.9	52
174	Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet, The, 2017, 390, 2769-2778.	13.7	3,705
175	Endoscopic and Histological Mucosal Healing in Ulcerative Colitis in the First Year of Diagnosis: Results from a Population-based Inception Cohort from Six Countries in Asia. Journal of Crohn's and Colitis, 2017, 11, 1440-1448.	1.3	14
176	A prospective study on second-generation colon capsule endoscopy to detect mucosal lesions and disease activity in ulcerative colitis (with video). Gastrointestinal Endoscopy, 2017, 86, 1139-1146.e6.	1.0	32
177	DNA of Erythroid Origin Is Present in Human Plasma and Informs the Types of Anemia. Clinical Chemistry, 2017, 63, 1614-1623.	3.2	63
178	Accuracy of Faecal Immunochemical Test to Predict Endoscopic and Histological Healing in Ulcerative Colitis: A Prospective Study Based on Validated Histological Scores. Journal of Crohn's and Colitis, 2017, 11, 1071-1077.	1.3	26
179	Understanding and Preventing the Global Increase of Inflammatory Bowel Disease. Gastroenterology, 2017, 152, 313-321.e2.	1.3	777
180	Micro <scp>RNA</scp> â€379 suppresses osteosarcoma progression by targeting <scp>PDK</scp> 1. Journal of Cellular and Molecular Medicine, 2017, 21, 315-323.	3.6	56

#	Article	IF	CITATIONS
181	Similar Efficacy of Proton-Pump Inhibitors vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin. Gastroenterology, 2017, 152, 105-110.e1.	1.3	43
182	Spontaneous type 1 pattern, ventricular arrhythmias and sudden cardiac death in Brugada Syndrome: an updated systematic review and meta-analysis. Journal of Geriatric Cardiology, 2017, 14, 639-643.	0.2	12
183	A meta-analysis of soluble suppression of tumorigenicity 2 (sST2) and clinical outcomes in pulmonary hypertension. Journal of Geriatric Cardiology, 2017, 14, 766-771.	0.2	10
184	Lentiviral Delivery of Small Hairpin RNA Targeting Connective Tissue Growth Factor Blocks Profibrotic Signaling in Tenon's Capsule Fibroblasts. , 2016, 57, 5171.		10
185	Changing epidemiological trends of inflammatory bowel disease in Asia. Intestinal Research, 2016, 14, 111.	2.6	250
186	The Same Intestinal Inflammatory Disease despite Different Genetic Risk Factors in the East and West?. Inflammatory Intestinal Diseases, 2016, 1, 78-84.	1.9	7
187	Screening strategies for colorectal cancer among patients with nonalcoholic fatty liver disease and family history. International Journal of Cancer, 2016, 138, 576-583.	5.1	13
188	Stratification of Digestive Cancers with Different Pathological Features and Survival Outcomes by MicroRNA Expression. Scientific Reports, 2016, 6, 24466.	3.3	35
189	Gastroduodenal Involvement in Asymptomatic Crohn's Disease Patients in Two Areas of Emerging Disease: Asia and Eastern Europe. Journal of Crohn's and Colitis, 2016, 10, 1401-1406.	1.3	10
190	Prevalence of hepatitis B and clinical outcomes in inflammatory bowel disease patients in a viral-endemic region. BMC Gastroenterology, 2016, 16, 100.	2.0	9
191	World Gastroenterology Organisation Global Guidelines Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2016, 50, 803-818.	2.2	138
192	Epidemiology of Inflammatory Bowel Disease from 1981 to 2014. Inflammatory Bowel Diseases, 2016, 22, 1954-1960.	1.9	95
193	Globalisation of inflammatory bowel disease: perspectives from the evolution of inflammatory bowel disease in the UK and China. The Lancet Gastroenterology and Hepatology, 2016, 1, 307-316.	8.1	158
194	The discriminatory capability of existing scores to predict advanced colorectal neoplasia: a prospective colonoscopy study of 5,899 screening participants. Scientific Reports, 2016, 6, 20080.	3.3	15
195	Infectionâ€related hospitalizations in the first year after inflammatory bowel disease diagnosis. Journal of Digestive Diseases, 2016, 17, 610-617.	1.5	11
196	Low-dose azathioprine is effective in maintaining remission in steroid-dependent ulcerative colitis: results from a territory-wide Chinese population-based IBD registry. Therapeutic Advances in Gastroenterology, 2016, 9, 449-456.	3.2	22
197	Risks of Bleeding Recurrence and Cardiovascular Events With Continued Aspirin Use After Lower Gastrointestinal Hemorrhage. Gastroenterology, 2016, 151, 271-277.	1.3	59
198	78 Incidence and Phenotype of Inflammatory Bowel Disease From 13 Countries in Asia-Pacific: Results From the Asia-Pacific Crohn's and Colitis Epidemiologic Study 2011-2013. Gastroenterology, 2016, 150, S21.	1.3	9

#	Article	IF	CITATIONS
199	High morbidity and mortality of Clostridium difficile infection and its associations with ribotype 002 in Hong Kong. Journal of Infection, 2016, 73, 115-122.	3.3	23
200	Critical Role of Antimicrobial Peptide Cathelicidin for Controlling <i>Helicobacter pylori</i> Survival and Infection. Journal of Immunology, 2016, 196, 1799-1809.	0.8	49
201	Risk of Advanced Adenomas in Siblings of Individuals With Advanced Adenomas: A Cross-Sectional Study. Gastroenterology, 2016, 150, 608-616.	1.3	25
202	Risk of Colorectal Neoplasia in Individuals With Self-Reported Family History: A Prospective Colonoscopy Study from 16 Asia-Pacific Regions. American Journal of Gastroenterology, 2016, 111, 1621-1629.	0.4	22
203	Dysregulated Lysine Acetyltransferase 2B Promotes Inflammatory Bowel Disease Pathogenesis Through Transcriptional Repression of Interleukin-10. Journal of Crohn's and Colitis, 2016, 10, 726-734.	1.3	26
204	Systematic Review and Meta-analysis: Phenotype and Clinical Outcomes of Older-onset Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 10, 1224-1236.	1.3	122
205	Natural History of Elderly-onset Ulcerative Colitis: Results from a Territory-wide Inflammatory Bowel Disease Registry. Journal of Crohn's and Colitis, 2016, 10, 176-185.	1.3	54
206	Early Course of Inflammatory Bowel Disease in a Population-Based Inception Cohort Study From 8 Countries in Asia and Australia. Gastroenterology, 2016, 150, 86-95.e3.	1.3	94
207	Increased expression of <i>Solute carrier family 12 member 5</i> via gene amplification contributes to tumour progression and metastasis and associates with poor survival in colorectal cancer. Gut, 2016, 65, 635-646.	12.1	39
208	<i>Carbonic anhydrase IV</i> inhibits colon cancer development by inhibiting the Wnt signalling pathway through targeting the WTAP–WT1–TBL1 axis. Gut, 2016, 65, 1482-1493.	12.1	125
209	Emerging Trends of Inflammatory Bowel Disease in Asia. Gastroenterology and Hepatology, 2016, 12, 193-6.	0.1	20
210	Emerging leadership lecture: Inflammatory bowel disease in <scp>A</scp> sia: Emergence of a " <scp>W</scp> estern―disease. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 440-445.	2.8	78
211	MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer. Cell Proliferation, 2015, 48, 503-510.	5.3	58
212	Identification of subjects at risk of proximal advanced neoplasia for colorectal cancer screening. European Journal of Cancer, 2015, 51, 37-44.	2.8	7
213	Prediction of proximal advanced neoplasia: a comparison of four existing sigmoidoscopy-based strategies in a Chinese population. Gut, 2015, 64, 776-783.	12.1	13
214	Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial. Clinical Gastroenterology and Hepatology, 2015, 13, 1444-1449.e1.	4.4	325
215	Dietary intake of inulin-type fructans in active and inactive Crohn's disease and healthy controls: a case–control study. Journal of Crohn's and Colitis, 2015, 9, 1024-1031.	1.3	33
216	Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nature Genetics, 2015, 47, 979-986.	21.4	1,965

#	Article	IF	CITATIONS
217	Factors Associated with Mucosal Healing in Patients with Ulcerative Colitis in Clinical Remission. Inflammatory Bowel Diseases, 2015, 21, 840-846.	1.9	6
218	Serrated Polyps and the Risk of Synchronous Colorectal Advanced Neoplasia: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology, 2015, 110, 501-509.	0.4	68
219	Targeted screening for colorectal cancer in high-risk individuals. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2015, 29, 941-951.	2.4	16
220	Dihydrotanshinone I induced apoptosis and autophagy through caspase dependent pathway in colon cancer. Phytomedicine, 2015, 22, 1079-1087.	5.3	58
221	Su1301 Incidence and Phenotype of Inflammatory Bowel Disease From 2012-2013 Across 9 Countries in Asia: Results From the 2012 Access Inception Cohort. Gastroenterology, 2015, 148, S-466.	1.3	1
222	Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer. Gut, 2015, 64, 636-645.	12.1	163
223	Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific. Gut, 2015, 64, 1063-1071.	12.1	320
224	PAQR3: a novel tumor suppressor gene. American Journal of Cancer Research, 2015, 5, 2562-8.	1.4	11
225	A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. Gut, 2014, 63, 1381-1392.	12.1	317
226	Thalidomide and Refractory Crohn's Disease. Journal of Clinical Gastroenterology, 2014, 48, 476-477.	2.2	5
227	Epidemiology of inflammatory bowel disease: Focus on Asia. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 363-372.	2.4	120
228	Xenophagy in <i>Helicobacter pylori</i> ―and Epstein–Barr virusâ€induced gastric cancer. Journal of Pathology, 2014, 233, 103-112.	4.5	27
229	Informed Choice vs. No Choice in Colorectal Cancer Screening Tests: A Prospective Cohort Study in Real-Life Screening Practice. American Journal of Gastroenterology, 2014, 109, 1072-1079.	0.4	30
230	Systematic review with metaâ€analysis: Accuracy of interferonâ€gamma releasing assay and antiâ€ <i><scp>S</scp>accharomyces cerevisiae</i> antibody in differentiating intestinal tuberculosis from <scp>C</scp> rohn's disease in <scp>A</scp> sians. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1664-1670.	2.8	66
231	Infections and inflammatory bowel disease: Challenges in <scp>A</scp> sia. Journal of Digestive Diseases, 2013, 14, 567-573.	1.5	17
232	Increased Risk of Advanced Neoplasms Among Asymptomatic Siblings of Patients With Colorectal Cancer. Gastroenterology, 2013, 144, 544-550.	1.3	47
233	Geographical variability and environmental risk factors in inflammatory bowel disease. Gut, 2013, 62, 630-649.	12.1	476
234	Reply. Gastroenterology, 2013, 145, 912.	1.3	0

#	Article	IF	CITATIONS
235	Incidence and Phenotype of Inflammatory Bowel Disease Based on Results From the Asia-Pacific Crohn's and Colitis Epidemiology Study. Gastroenterology, 2013, 145, 158-165.e2.	1.3	633
236	A novel crosstalk between two major protein degradation systems. Autophagy, 2013, 9, 1500-1508.	9.1	143
237	Impact of Ethnicity, Geography, and Disease on the Microbiota in Health and Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2013, 19, 2906-2918.	1.9	79
238	MicroRNA-10b Promotes Nucleus Pulposus Cell Proliferation through RhoC-Akt Pathway by Targeting HOXD10 in Intervetebral Disc Degeneration. PLoS ONE, 2013, 8, e83080.	2.5	166
239	Inflammatory bowel disease serology in Asia and the West. World Journal of Gastroenterology, 2013, 19, 6207.	3.3	21
240	Inflammatory bowel disease in Asia. Gastroenterology and Hepatology, 2013, 9, 28-30.	0.1	8
241	Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for crohn's perianal fistulas. Inflammatory Bowel Diseases, 2012, 18, 1825-1834.	1.9	114
242	Genetics of inflammatory bowel disease in Asia: Systematic review and meta-analysis. Inflammatory Bowel Diseases, 2012, 18, 1164-1176.	1.9	151
243	Comparison of clinical characteristics and management of inflammatory bowel disease in Hong Kong versus Melbourne. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 919-927.	2.8	34
244	Inflammatory bowel disease in Asia: A systematic review. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1266-1280.	2.8	283
245	Narrowâ€band imaging in the colon: Limitations and potentials. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 1589-1596.	2.8	25
246	RNA interference targeting raptor inhibits proliferation of gastric cancer cells. Experimental Cell Research, 2011, 317, 1353-1358.	2.6	7
247	Technical Advances in Getting to the Cecum. Current Colorectal Cancer Reports, 2011, 7, 16-23.	0.5	1
248	Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. Gut, 2011, 60, 923-929.	12.1	288
249	Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis. Inflammatory Bowel Diseases, 2010, 16, 1286-1298.	1.9	112
250	The host defense peptide LLâ€37 activates the tumorâ€suppressing bone morphogenetic protein signaling via inhibition of proteasome in gastric cancer cells. Journal of Cellular Physiology, 2010, 223, 178-186.	4.1	72
251	NSAID-induced gastrointestinal and cardiovascular injury. Current Opinion in Gastroenterology, 2010, 26, 611-617.	2.3	78
252	Proteasome inhibition: A new therapeutic strategy to cancer treatment. Cancer Letters, 2010, 293, 15-22.	7.2	86

#	Article	IF	CITATIONS
253	Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: An update on the molecular mechanisms. Cancer Letters, 2010, 295, 7-16.	7.2	138
254	Macroautophagy and ERK phosphorylation counteract the anti-proliferative effect of proteasome inhibitor in gastric cancer cells. Autophagy, 2010, 6, 228-238.	9.1	41
255	Inhibition of cyclooxygenase-1 lowers proliferation and induces macroautophagy in colon cancer cells. Biochemical and Biophysical Research Communications, 2009, 382, 79-84.	2.1	13
256	Repression of protein translation and mTOR signaling by proteasome inhibitor in colon cancer cells. Biochemical and Biophysical Research Communications, 2009, 386, 598-601.	2.1	23
257	Expression of ErbB receptors and their cognate ligands in gastric and colon cancer cell lines. Anticancer Research, 2009, 29, 229-34.	1.1	27
258	Involvement of voltage-gated K+ and Na+ channels in gastric epithelial cell migration. Molecular and Cellular Biochemistry, 2008, 308, 219-226.	3.1	15
259	Proteasome inhibitor MG-132 lowers gastric adenocarcinoma TMK1 cell proliferation via bone morphogenetic protein signaling. Biochemical and Biophysical Research Communications, 2008, 371, 209-214.	2.1	13
260	Constitutive hypophosphorylation of extracellular signal-regulated kinases-1/2 and down-regulation of c-Jun in human gastric adenocarcinoma. Biochemical and Biophysical Research Communications, 2008, 373, 330-334.	2.1	8
261	Induction of autophagy by proteasome inhibitor is associated with proliferative arrest in colon cancer cells. Biochemical and Biophysical Research Communications, 2008, 374, 258-263.	2.1	79
262	Perianal Fistulizing Crohn's Disease: A Call to Action. Clinical Gastroenterology and Hepatology, 2008, 6, 7-10.	4.4	57
263	Involvement of Kv1.1 and Nav1.5 in proliferation of gastric epithelial cells. Journal of Cellular Physiology, 2006, 207, 437-444.	4.1	25
264	Heparin increases human gastric carcinoma cell growth. Anticancer Research, 2006, 26, 439-43.	1.1	3
265	Implications of the COVID-19 Pandemic on the Management of Inflammatory Bowel Disease in the Low Resource Countries of Asia. European Medical Journal Gastroenterology, 0, , .	0.0	0
266	Childhood antibiotics as a risk factor for Crohn's disease: The <scp>ENIGMA</scp> International Cohort Study. JGH Open, 0, , .	1.6	2